52-67-5
52-67-5
Chemical Structure
Penicillamine
Synonym(s): D-(-)-Penicillamine
- CAS No.: 52-67-5
- Formula:C5H11NO2S
- Molecular Weight:149.22
IUPAC Name: (S)-2-amino-3-mercapto-3-methylbutanoic acid
InChIKey: VVNCNSJFMMFHPL-VKHMYHEASA-N
SMILES: N[C@H](C(C)(S)C)C(O)=O
Biological Activity: Penicillamine (D-(-)-Penicillamine) is a penicillin metabolic degradation product, can be used as a heavy metal chelator. Penicillamine increases free copper and increases oxidative stress. Penicillamine has effect of seizures through nitric oxide/NMDA pathways. Penicillamine is a potential immune modulator. Penicillamine can be used for the research of Wilson disease, rheumatoid arthritis, and cystinuria[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Penicillamine | 98.0% | Penicillamine (D-(-)-Penicillamine) is a penicillin metabolic degradation product, can be used as a heavy metal chelator. Penicillamine increases free copper and increases oxidative stress. Penicillamine has effect of seizures through nitric oxide/NMDA pathways. Penicillamine is a potential immune modulator. Penicillamine can be used for the research of Wilson disease, rheumatoid arthritis, and cystinuria. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Penicillamine (Standard) | ≥98% | Penicillamine (Standard) is the analytical standard of Penicillamine. This product is intended for research and analytical applications. Penicillamine (D-(-)-Penicillamine) is a penicillin metabolic degradation product, can be used as a heavy metal chelator. Penicillamine increases free copper and increases oxidative stress. Penicillamine has effect of seizures through nitric oxide/NMDA pathways. Penicillamine is a potential immune modulator. Penicillamine can be used for the research of Wilson disease, rheumatoid arthritis, and cystinuria. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Penicillamine-d3 | Penicillamine-d3 is the deuterium labeled Penicillamine. Penicillamine (D-(-)-Penicillamine) is the most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Penicillamine | 99.71% | L-Penicillamine is an orally active serine palmitoyltransferase (SPT) inhibitor. L-Penicillamine inactivates the PLP cofactor by forming adducts, thereby inhibiting SPT activity and reducing sphingolipid biosynthesis. L-Penicillamine not only blocks tumor access to vitamin B6, but also stabilizes the human papillomavirus 16 E6 oncoprotein monomer and inhibits its polymerization, exhibiting a unique anticancer mechanism. L-Penicillamine effectively delays the growth of Sarcoma-180, induces tumor necrosis and prolongs survival (though long-term use may lead to Pyridoxine (HY-B1328) deficiency and weight loss). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Valine-d1 | L-Valine-d is the deuterium labeled L-Valine (HY-N0717). L-Valine ((S)-Valine) is a nonlinear semiorganic material. L-Valine causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(S)-2-Amino-3,3-dimethylbutanoic acid | 98.0% | (S)-2-amino-3,3-dimethylbutanoic acid is a leucine derivative. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
4-Methyl-L-leucine | 97.0% | 4-Methyl-L-leucine is a Glycine (HY-Y0966) derivative. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-a-tert-Butyl-Gly-OH | 98.0% | D-a-tert-Butyl-Gly-OH is a leucine derivative. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2-Amino-3,3-dimethylbutanoic acid | 98.0% | 2-Amino-3,3-dimethylbutanoic acid is a leucine derivative. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Valine-d-1 | DL-Valine-d-1 is the deuterium labeled DL-Valine. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Penicillamine (Standard) | ≥98% | DL-Penicillamine (Standard) is the analytical standard of DL-Penicillamine. This product is intended for research and analytical applications. DL-Penicillamine [(±)-Penicillamine] is a copper chelating agent. DL-Penicillamine has antidotal effects in thallotoxicosis rats when co-treated with Prussian blue (HY-106594A). DL-Penicillamine can cause pyridoxine deficiency and then induce optic axial neuritis. DL-Penicillamine can also depress primary immune response. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3-Fluoro-DL-valine | 3-Fluoro-DL-valine (3-Fluorovaline) is an unnatural amino acid that has the activity of inhibiting the growth of certain bacteria. 3-Fluoro-DL-valine can also be used in peptide synthesis, providing a variety of options for the synthesis of specific bioactive peptides. The unique structure of 3-Fluoro-DL-valine makes it a potential application prospect in compound research and development. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
S-Methyl-D-penicillamine | S-Methyl-D-penicillamine is a metabolite of the chelating agent Penicillamine (HY-B0300). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Chen DB, et, al. Penicillamine increases free copper and enhances oxidative stress in the brain of toxic milk mice. PLoS One. 2012;7(5):e37709. [Content Brief]
- [2]. Rahimi N, et, al. Effects of D-penicillamine on pentylenetetrazole-induced seizures in mice: involvement of nitric oxide/NMDA pathways. Epilepsy Behav. 2014 Oct;39:42-7. [Content Brief]
- [3]. Masson MJ, et, al. Tolerance induced by low dose D-penicillamine in the brown Norway rat model of drug-induced autoimmunity is immune-mediated. Chem Res Toxicol. 2004 Jan;17(1):82-94. [Content Brief]
- [4]. Ishak R, et, al. Penicillamine revisited: historic overview and review of the clinical uses and cutaneous adverse effects. Am J Clin Dermatol. 2013 Jun;14(3):223-33. [Content Brief]
